natgillin/translations-raw huggingface dataset:
The composition or kit for use according to claim 1 or claim 2, wherein the neurological disorder is a neurodegenerative disease or a traumatic injury to the brain. 
Sastav ili set za korištenje prema zahtjevu 1 ili zahtjevu 2, naznačen time da je naurološki poremećaj neurodegenerativna bolest ili traumatska ozljeda mozga.
A composition or kit consisting of as active ingredients the following four components: 
Sastav ili set za korištenje koji obuhvaća od aktivnih sastojaka sljedeće četiri komponente:
The composition or kit according to claim 7 comprising a pharmaceutically acceptable additive, carrier or diluent. 
Sastav ili set za korištenje prema zahtjevu 7, koji obuhvaća farmaceutski prihvatljiv aditiv, nosač ili razrjeđivač.
A combination comprising (i) a compound of Formula I: or a pharmaceutically acceptable salt thereof and (ii) one or more anti-HIV agent selected from HIV antiviral agents, immunomodulators and anti-infective agents, wherein: 
Kombinacija koja sadrži (i) spoj formule I: [image] ili njegovu farmaceutski prihvatljivu sol i (ii) jedno ili više sredstava protiv HIV-a izabranih od antivirusnih sredstava protiv HIV-a, imunomodulatora i anti-infektivnih sredstava, gdje:
The combination according to claim 1 or claim 2, wherein the one or more anti-HIV agent is an antiviral selected from HIV protease inhibitors, nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV fusion inhibitors and HIV entry inhibitors. 
Kombinacija prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačena time što jedno ili više sredstava protiv HIV-a je antivirusno sredstvo izabrano od inhibitora HIV proteaze, nukleozidnih inhibitora HIV reverzne transkriptaze, nenukleozidnih inhibitora HIV reverzne transkriptaze, inhibitora HIV integraze, inhibitora fuzije HIV-a i inhibitora ulaska HIV-a.
The combination according to any one of claims 1-4, for use in the treatment of infection by HIV, the treatment of AIDS, or the delay of onset of AIDS in a subject. 
Kombinacija prema bilo kojem od patentnih zahtjeva 1-4, za uporabu u liječenju infekcije HIV-om, liječenju SIDA-e, ili odlaganju početka SIDA-e kod subjekta.
The bilirubin nanoparticle of claim 1, wherein the bilirubin nanoparticle generates reactive oxygen species by light. 
Čestica bilirubina prema zahtjevu 1, naznačena time što čestica bilirubina stvara reaktivne kisikove vrste sa svjetlošću.
A pharmaceutical composition for preventing or treating a cancer, the pharmaceutical composition containing: (a) a pharmaceutically effective amount of the bilirubin nanoparticle of any one of claims 1 to 15; and (b) a pharmaceutically acceptable carrier. 
Farmaceutski pripravak za uporabu u liječenju ili sprječavanju raka, farmaceutski pripravak sadrži: (a) farmaceutski učinkovitu količinu čestice bilirubina prema bilo kojem od zahtjeva 1 do 8; i (b) farmaceutski prihvatljivi nosač.
A pharmaceutical composition for preventing or treating an inflammatory disease, the pharmaceutical composition containing: (a) a pharmaceutically effective amount of the bilirubin nanoparticle of any one of claims 1 to 15; and (b) a pharmaceutically acceptable carrier. 
Farmaceutski pripravak za uporabu u liječenju ili sprječavanju upalne bolesti, farmaceutski pripravak sadrži: (a) farmaceutski učinkovitu količinu čestice bilirubina prema bilo kojem od zahtjeva 1 do 8; i (b) farmaceutski prihvatljivi nosač.
A pharmaceutical composition for preventing or treating an angiogenesis-related disease, the pharmaceutical composition containing: (a) a pharmaceutically effective amount of the bilirubin nanoparticle of any one of claims 1 to 15; and (b) a pharmaceutically acceptable carrier. 
Farmaceutski pripravak za uporabu u liječenju ili sprječavanju bolesti povezanih s angiogenezom, farmaceutski pripravak sadrži: (a) farmaceutski učinkovitu količinu čestice bilirubina prema bilo kojem od zahtjeva 1 do 8; i (b) farmaceutski prihvatljivi nosač.
A method for preparing a bilirubin nanoparticle, the method comprising: 
Postupak za pripremu čestice bilirubina, koji sadrži:
preparing a bilirubin-hydrophilic polymer composite by binding a hydrophilic polymer to bilirubin; 
pripremu bilirubin-hidrofilnog polimernog kompozita vezanjem hidrofilnog polimera na bilirubin;
removing the chloroform or dimethyl sulfoxide to form a bilirubin-hydrophilic polymer composite film layer; and 
uklanjanjem kloroforma ili dimetil sulfoksida da nastane sloj filma kompozita bilirubin-hidrofilni polimer; i
A compound of formula (VIII), or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 11, for use in the treatment of a TRPA1 mediated disorder selected from the group consisting of acute and/or chronic pain, touch sensitivity, burns, inflammation, diabetic neuropathy, psoriasis, eczema, dermatitis, post-herpetic neuralgia, migraine, incontinence, fever, hot flashes, osteoarthritis, oral mucositis, cancer pain, bladder cystitis, pain associated with Crohn's disease and Irritable Bowel Syndrome (IBS), rheumatoid arthritis, Grierson-Gopalan syndrome, burning mouth syndrome (BMS) and cough, or in depilation to promote loss of or inhibit the growth of hair on a patient. 
Spoj formule (VIII′) u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju poremećaja kod kojeg posreduje TRPA1 kojeg se bira iz skupine koju čine akutna i/ili kronična bol, osjetljivost na dodir, opekline, upala, dijabetična neuropatija, psorijaza, egzem, dermatitis, postherpetična neuralgija, migrena, inkontinencija, groznica, napadaji vrućine, osteoartritis, oralni mukozitis, bol uzrokovana rakom, cistitis mokraćnog mjehura, bol povezana s Crohnovom bolešću i sindrom iritabilnih crijeva (IBS), reumatoidni artritis, Grierson-Gopalanov sindrom, sindrom pečenja u ustima (BMS) i kašalj, ili kod depilacije radi poticanja gubitka ili inhibiranja rasta dlaka kod pacijenta.
wherein the HIV gp140 trimer is capable of eliciting production of neutralizing antisera against HIV when administered to a subject. 
gdje HIV gp140 trimer trimer može izazvati proizvodnju neutralizacijskih antiseruma protiv HIV - a kada se stabilizirani trimer daje subjektu.
An HIV gp140 trimer according to claim 1 or claim 2, wherein the trimerization domain is the T4-fibritin foldon trimerization domain. 
HIV gp 140 trimer sukladno zahtjevima 1 ili 2, gdje je trimerizacijska domena T4-fibritin fold trimerizacijska domena.
An HIV gp140 trimer according to any one of claims 1-7, or a pharmaceutical composition according to claim 8, for use as a vaccine. 
HIV gp 140 trimer, sukladno zahtjevima 1 – 7, ili farmaceutski spoj, sukladno zahtjevu 8. za korištenje kao cjepiva.
An HIV gp140 trimer according to any one of claims 1-7, or a pharmaceutical composition according to claim 8, or a vaccine according to claim 10 or claim 11, for use in a method of producing neutralizing antisera against HIV after injection into a subject. 
HIV gp 140 trimer sukladno patentnim zahtjevima 1 – 7 ili farmaceutski spoj sukladno patentnom zahtjevu 8, ili cjepivo sukladno patentnim zahtjevima 10 ili 11, naznačeni time, što se koristi kao postupak za proizvodnju neutralizirajućih seruma protiv HIV-a nakon injektiranja u subjekta.
An HIV gp140 trimer according to any one of claims 1-7, or a pharmaceutical composition according to claim 8, or a vaccine according to claim 10 or claim 11, for use in immunizing a subject against HIV. 
HIV gp 140 trimer, sukladno patentnim zahtjevima 1- 7, ili farmaceuski spoj sukladno zahtjevu 8, ili cjepivo sukladno patentnim zahtjevima 10 ili 11, za uporabu za imunizaciju subjekta protiv HIV-a.
adding to the mixture a solution comprising ethylenediaminetetracetic acid; 
dodavanje u smjesu otopine koja sadrži etilendiamintetraoctenu kiselinu;
heating and mechanically stirring the resulting mixture until the compound has fully dispersed within the mixture; 
zagrijavanje i mehaničko miješanje dobivene smjese sve dok se spoj potpuno ne rasprši unutar smjese;
diluting the mixture such that the final concentration of the compound in solution is at least 300 mg per 1 milliliter. 
razrjeđivanje smjese tako da konačna koncentracija spoja u otopini iznosi najmanje 300 mg po 1 mililitru.
a leaflet assembly (102) positioned within the frame (104), the leaflet assembly comprising a plurality of leaflets (106) that are connected to each other to form commissures of the leaflet assembly (102); 
sklop jedra (102) smješten unutar okvira (104), te sklop jedra sadrži mnoštvo jedara (106) koja su međusobno spojena tako da tvore spojišta sklopa jedra (102);
wherein the frame (104) comprises a pair of struts (404, 406) adjacent each of the commissures, the struts of each pair being spaced apart from each other so as to define an opening (420) therebetween; 
pri čemu okvir (104) sadrži par okomitih nosača (404, 406) koji su susjedni svakom od spojišta, te su nosači svakog para međusobno razmaknuti tako da između njih definiraju otvor (420);
The assembly of any one of the preceding claims, wherein the vertical struts (404, 406) of each pair are connected to each other at their upper ends. 
Protetski zalistak koji se može implantirati prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što su okomiti nosači (404, 406) svakog para međusobno spojeni na njihovim gornjim krajevima.
the frame (104) comprises an upper frame section and a lower frame section, the upper frame section having a plurality of struts and a first leaflet receiving surface at a lower portion of the upper frame section, the lower frame section having a second leaflet receiving surface at an upper portion of the lower frame section; 
okvir (104) sadrži gornji dio okvira i donji dio okvira, te gornji dio okvira ima mnoštvo nosača i površinu za prihvaćanje prvog jedra na donjem dijelu gornjeg dijela okvira, te donji dio okvira ima površinu za prihvaćanje drugog jedra na gornjem dijelu donjeg dijela okvira;
providing a radially collapsible and expandable annular frame (104), the frame comprising a plurality of circumferentially spaced pairs of vertical struts (404, 406), the struts of each pair being spaced apart from each other so as to define an opening (420) therebetween; 
osiguravanje radijalno sklopivog i proširivog prstenastog okvira (104), pri čemu okvir sadrži mnoštvo obodno raspoređenih parova okomitih nosača (404, 406), pri čemu su nosači svakog para međusobno razmaknuti tako da između njih definiraju otvor (420);
providing a leaflet assembly (102) comprising a plurality of leaflets (106); 
osiguravanje sklopa jedra (102) koji sadrži mnoštvo jedara (106);
inserting a pair of adjacent leaflets (106a, 106b) through the opening (420) of each pair of vertical struts (404, 406); 
umetanje para susjednih jedara (106a, 106b) kroz otvor (420) svakog para okomitih nosača (404, 406);
The method of claim 10 or 11, further comprising securing the lower edge portion of each leaflet to the frame after suturing the cloth portions (304) to the leaflets. 
Postupak prema patentnom zahtjevu 10 ili 11, naznačen time što dodatno sadrži osiguravanje dijela donjeg ruba svakog jedra na okvir nakon pričvršćivanja šavovima dodatnih dijelova tkanine (304) na jedra.
A station for heating a plurality of portions (2) of ends of pipes (3) made of thermoplastic material, comprising: 
Stanica za zagrijavanje velikog broja dijelova (2) krajeva cijevi (3) izrađenih od termoplastičnog materijala, koja sadrži:
a plurality of heating elements (7, 8, 9, 14) equipped with short wave radiation units (10), 
veliki broj elemenata (7, 8, 9, 14) za zagrijavanje opremljenih kratkovalnim zračnim jedinicama (10),
The station according to claim 1 or 2, characterised in that the cell (5) comprises a reflective surface (15) designed to face the pipe (3) for at least half the angular extension of a relative outer cylindrical surface (2a). 
Stanica prema patentnom zahtjevu 1 ili 2, naznačena time da stanica (5) sadrži reflektivnu površinu (15) dizajniranu da je okrenuta prema cijevi (3) za najmanje polovinu kutnog produžetka odnosne vanjske cilindrične površine (2a).
The station according to claim 5, characterised in that the reflective surface (15) with a curved extension is positioned at the lower zone (5b) of the cell (5). 
Stanica prema patentnom zahtjevu 5, naznačena time da reflektivna površina (15) sa zakrivljenim produžetkom je pozicionirana u donjoj zoni (5b) stanice (5).
A belling machine for multi-belling of pipes (3) made of thermoplastic material, to simultaneously form bells on respective ends (2) of a plurality of tubes (3), comprising: 
Stroj za formiranje zvonastih završetaka za višestruko formiranje zvonastih završetaka cijevi (3) izrađenih od termoplastičnog materijala, za istovremeno oblikovanje zvonastih završetaka na odgovarajućim krajevima (2) velikog broja cijevi (3), koja sadrži:
a station for forming bells on the ends (2) of the pipes (3), the station comprising a plurality of forming spindles. 
stanica za oblikovanje zvonastih završetaka na krajevima (2) cijevi (3), stanica koja sadrži veliki broj vretena za oblikovanje.
A method for heating portions (2) of ends of pipes (3) made of thermoplastic material comprising the steps of: 
Metoda za zagrijavanje dijelova (2) krajeva cijevi (3) izrađenih od termoplastičnog materijala koja obuhvaća korake:
A hydraulic hinge for rotatably moving and controlling a closing element anchored to a stationary support structure between an open position and a closed position, the hydraulic hinge comprising: 
Hidraulična šarka male masivnosti za rotatabilno pomicanje i kontroliranje elementa (A) za zatvaranje, poput vrata, poklopca ili slično, učvršćena na stacionarnu potpornu strukturu (S), kao što je zid ili okvir, između otvorenog položaja i zatvorenog položaja, pri čemu šarka sadrži:
A compound having the structure: 
Spoj naznačen time, da ima strukturu:
wherein Xa is a chemical structure containing a cyclooctane fused to a dihydropyridazine; wherein Ra represents an organic structure which connects to one of A or B and Rb represents an organic structure which connects to the other of A or B. 
[image] u čemu Xa jest kemijska struktura koja sadrži ciklooktan kondenziran na dihidropiridazin; u čemu Ra predstavlja organsku strukturu koja se veže na jedno od A ili B, a Rb predstavlja organsku strukturu koja se veže na drugo od A ili B.
The compound according to claim 1 wherein Ra is connected to the cyclooctane and Rb is connected to the dihydropyridazine. 
Spoj prema patentnom zahtjevu 1, naznačen time, da je Ra vezan na ciklooktan, a Rb je vezan na dihidropiridazin.
ix) comprises a branched residue; or 
ix) sadrži razgranani ostatak; ili
comprises the structure of a compound that is a drug approved for treating a subject afflicted with a disease; 
sadrži strukturu spoja koji je lijek, odobren za liječenje pacijenta pogođenog bolešću;
iv) is linked to B via the primary or secondary amine; 
iv) jest vezan na B preko primarnog ili sekundarnog amina;
vi) comprises a secondary amine; 
vi sadrži sekundarni amin;
comprises a secreted protein; 
sadrži sekretorni protein;
xxiv) comprises Fab-2 or Fab'2, or a portion thereof of an antibody; 
xxiv) sadrži Fab-2 ili Fab’2, ili njihov dio od antitijela;
xxv) comprises two Fab or Fab' hands of an antibody; 
xxv) sadrži dvije ruke od Fab ili Fab’ od antitijela;
is an organic structure comprising a [PEG(y)]z group; 
jest organska struktura koja sadrži [PEG(y)]z skupinu;
iii) is an organic structure comprising a C1-C4 alkyl group 
iii) jest organska struktura koja sadrži C1-C4 alkilnu skupinu;
is an organic structure comprising an amine; 
jest organska struktura koja sadrži amin;
vii) is an organic structure comprising a malonyl; 
vii) jest organska struktura koja sadrži malonil;
ix) is an organic structure comprising a cysteine; 
ix) jest organska struktura koja sadrži cistein;
is an organic structure comprising a lysine; 
jest organska struktura koja sadrži lizin;
xxi) has a linear structure; or xxii) has a branched structure; 
xxi) ima linearnu strukturu; ili xxii) ima razgnananu strukturu;
xxiii) has the structure: 
xxiii) ima strukturu:
The compound according to any one of claims 1-8, wherein Z comprises one C, wherein C is a first polypeptide, which first popyleptide comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence selected from the group consisting of a cysteine, selenocysteine, CP, CPXCP (where X = P, R, or S), CDKTHTCPPCP, CVECPPCP, CCVECPPCP and CDTPPPCPRCP. 
Spoj prema bilo kojem od patentnih zahtjeva 1 - 8,naznačen time, da Z sadrži jedan C, u čemu C jest prvi polipeptid, koji prvi polipeptid sadrži aminokiseline u slijedu koje (i) su identične s odsječkom aminokiselina u slijedu prisutnih u lancu Fc domene antitijela; (ii) vežu se na Fc receptor; i (iii) imaju na njihovom N-terminusu sekvencu izabranu iz skupine koja se sastoji od cisteina, selenocisteina, CP, CPXCP (gdje X = P, R, ili S), CDKTHTCPPCP, CVECPPCP, CCVECPPCP i CDTPPPCPRCP.
comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence comprising a naturally occurring cysteine selected from the group consisting of CP, CPXCP (where X = P, R, or S), CDKTHTCPPCP, CVECPPCP, CCVECPPCP and CDTPPPCPRCP; 
sadrži aminokiseline u slijedu koje (i) su identične odsječku aminokiselina u slijedu prisutnih u lancu Fc domene antitijela; (ii) vežu se na Fc receptor; i (iii) imaju na svojem N-terminusu sekvencu koja sadrži cistein koji se prirodno pojavljuje, odabran iz skupine koja se sastoji od CP, CPXCP (gdje X = P, R,ili S), CDKTHTCPPCP, CVECPPCP, CCVECPPCP i CDTPPPCPRCP;
ii) is a polypeptide component of the compound, which polypeptide component comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence comprising a non-naturally occurring cysteine or selenocysteine; 
ii) jest polipeptidna komponenta spoja, koja polipeptidna komponenta sadrži aminokiseline u slijedu koje (i) su identične s odsječkom aminokiselina u slijedu prisutnih u lancu Fc domene antitijela; (ii) vežu se na Fc receptor; i (iii) imaju na svojem N-terminusu sekvencu koja sadrži cistein ili selenocistein koji se prirodno ne pojavljuje;
iii) comprises consecutive amino acids which are identical to a stretch of consecutive amino acids present in the chain of an Fc domain of an antibody selected from the group consisting of IgG, IgM, IgA, IgD, and IgE; 
sadrži aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u lancu Fc domene antitijela izabranih iz skupine koja se sastoji od IgG, IgM, IgA, IgD, i IgE;
iv) comprises consecutive amino acids which are identical to a stretch of consecutive amino acids present in the chain of an Fc6 domain of an antibody 
iv) sadrži aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u lancu Fc6 domene antitijela;
comprises consecutive amino acids which are identical to a stretch of consecutive amino acids present in a chain of an antibody other than a chain of a Fc domain of the antibody; 
sadrži amino kiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u lancu antitijela različitom od lanca Fc domene antitijela;
vi) consecutive amino acids which are identical to a stretch of consecutive amino acids present in a heavy chain of a Fab or a Fab' of an antibody; or vii) comprises consecutive amino acids which are identical to a stretch of consecutive amino acids present in the light chain of a Fab or a Fab' of an antibody. 
vi) aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u teškom lancu od Fab ili Fab’ antitijela; ili vii) sadrži aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u laganom lancu od Fab ili Fab’ antitijela.
The compound according to claim 11, wherein the second popypeptide comprises consecutive amino acids which are identical to a stretch of consecutive amino acids present in a heavy chain of a Fab or a Fab' of an antibody; or ii) consecutive amino acids which are identical to a stretch of consecutive amino acids present in the light chain of a Fab or a Fab' of an antibody. 
Spoj prema patentnom zahtjevu 11, naznačen time, da drugi polipeptid sadrži aminokiseline u slijedu koje su identične s odsječkom amino kiselina u slijedu prisutnih u teškom lancu od Fab ili Fab’ antitijela; ili ii) aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u laganom lancu od Fab ili Fab’ antitijela.
comprises an antibody or a portion thereof; 
sadrži antitijelo ili njegov dio;
iii) comprises Fab-1 or Fab'1, or a portion thereof of an antibody; 
iii) sadrži Fab-1 ili Fab’1, ili njihov dio od antitijela;
iv) comprises Fab-2 or Fab'2, or a portion thereof of an antibody; 
iv) sadrži Fab-2 ili Fab’2, ili njihov dio od antitijela;
comprises two Fab or Fab' hands of an antibody; 
sadrži dvije ruke od Fab ili Fab’ antitijela;
iii) is bound to the other by at least one disulfide bond; 
iii) je vezan na drugi preko barem jedne disulfidne veze;
The method of claim 4, wherein each of Ar1 and Ar2 is a phenyl group substituted with 0, 1, or 2 J groups. 
Spoj sukladno patentnom zahtjevu 6, pri čemu je svaka od Ar1 i Ar2 fenil skupina supstituirana s 0, 1, ili 2 J skupinama.
The method of claim 4, wherein the compound of formula (I) is formula 2 
Spoj sukladno patentnom zahtjevu 5, pri čemu je spoj od formule (I) formula 2 [image]
The method of claim 1, wherein the sugar is provided in the form of an aqueous sugar solution, wherein the aqueous sugar solution has a concentration of 5-60 wt %. 
Postupak za pripremu diola prema patentnom zahtjevu 1, naznačen time što šećer reagira s vodikom u obliku vodene otopine šećera, i polazni materijal vodene otopine šećera ima koncentraciju 5 - 60 mas.%.
The method of claim 1, wherein the insoluble tungsten compound is selected from tungsten trioxide, tungstic acid and a combination thereof. 
Postupak za pripremu diola prema patentnom zahtjevu 1, naznačen time što je netopivi volframov spoj volfram trioksid i / ili volframova kiselina.
An application of a dimethylamino micheliolide in preparing a pharmaceutical product for treating pulmonary fibrosis, wherein the dimethylamino micheliolide has a molecular structural formula of: 
Dimetilamino-mikeliolid za uporabu u postupku liječenja plućne fibroze, pri čemu dimetilamino mikeliolid ima molekulsku strukturnu formulu od:
The application according to claim 1, characterized in that the pharmaceutical product used to treat pulmonary fibrosis comprising the dimethylamino micheliolide, pharmaceutically-acceptable salts, esters, hydrates or their combinations, and excipients of the dimethylamino micheliolide. 
Farmaceutski pripravak, naznačen time, da sadrži dimetilamino-mikeliolid u skladu s patentnim zahtjevom 1, ili njegove farmaceutski prihvatljive soli, esteri, hidrati ili kombinacije i pomoćne tvari za uporabu u postupku liječenja plućne fibroze.
Pneumatic leaf remover head comprising: 
Glava pneumatskog odstranjivača lišća koja sadrži:
said protection plate (7) is fixed to said rotor (5) in an integral manner, so as to rotate with it; 
navedena zaštitna ploča (7) je integralno pričvršćena na navedeni rotor (5), tako da rotira sa njim;
said at least one deflector is at least one hole (73), each one arranged close to said at least one nozzle (33); said leaf remover head is characterized in that said protection plate (7) comprises: 
navedeni najmanje jedan deflektor je najmanje jedna rupa (73), od kojih je svaka postavljena blizu navedene najmanje jedne mlaznice (33); gdje navedena zaštitna ploča (7) sadrži:
Leaf remover head according to claim 1, wherein said peripheral portion (72) comprises: 
Glava odstranjivača listova prema patentnom zahtjevu 1, gdje navedeni obodni dio (72) sadrži: